



Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells




Yasmine Boumahd¹, Gilles Rademaker^{1,2}, Raphaël Peiffer¹, Sandy Anania¹, Ferman Agirman¹, Naïma Maloujahmoum¹, Akeila Bellahcène¹, Olivier Peulen,¹


1 Metastasis Research Laboratory, GIGA-cancer, University of Liège, Pathology Institute B23, B-4000 Liège, Belgium

2 Department of Anatomy, University of California, San Francisco, San Francisco, CA 94143, USA



Pancreatic ductal adenocarcinoma (PDAC) is the seventh leading cause of cancer-related deaths worldwide and it is estimated that PDAC will become the second leading cause of cancer-related death by 2030. Myoferlin is a protein implicated in membrane fusion and in receptor recycling. It allows the formation of vesicles for the trafficking in cells. In PDAC, myoferlin is overexpressed in high grades in comparison to low grades. We used an innovative small compound (WJ460) to target myoferlin in PDAC cell lines and reported the triggering of an iron-dependent cell death, namely ferroptosis, considered as an alternative to apoptosis in cancer cells.





The mortality rate of PDAC is currently almost equal to its incidence and its 5-year survival rate is the lowest among all cancers. In this study, we described that WJ460, a small compound binding to myoferlin, induced the same main biological effects than myoferlin gene silencing in several PDAC cell lines. Important iron pool is naturally present within tumors. Interestingly, erastin and RSL3, two ferroptosis inducers, were reported to be particularly efficient in KRAS-mutated cancer cells. More than 90% of PDACs carry mutated KRAS alleles, as such, ferroptosis has been proposed as an alternative to treat patients with KRAS mutation. Our results demonstrate that myoferlin targeting induces an iron-dependent cell death in PDAC cell lines.

